Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05509816 · ClinicalTrials.gov registry record · Phase 1
A Study of Imlunestrant (LY3484356) in Healthy Women
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05509816 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 20 participants.
The verdict
NCT05509816, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the effect of imlunestrant (LY3484356) when administered orally on the levels of midazolam in the blood stream in healthy women of non-childbearing potential. The study will also evaluate the safety and tolerability of imlunestrant in healthy women of non-childbearing potential. This study will last up to approximately 6 weeks for each participant including the screening period.
Interventions
- DRUG Midazolam
- DRUG Imlunestrant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-09-12 |
| Est. Completion | 2022-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05509816
The ClinicalTrials.gov registry entry for NCT05509816 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Midazolam is the first listed.
NCT05509816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05509816 about?
NCT05509816 is a clinical study titled "A Study of Imlunestrant (LY3484356) in Healthy Women". The main purpose of this study is to evaluate the effect of imlunestrant (LY3484356) when administered orally on the levels of midazolam in the blood stream in healthy women of non-childbearing potential. The study will also evaluate the safety and tolerability of imlunestrant in healthy women of no...
What is the current status of trial NCT05509816?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-09-12. Estimated completion is 2022-11-30.
What interventions are being tested in trial NCT05509816?
The interventions under investigation include: Midazolam (DRUG), Imlunestrant (DRUG).
Who is sponsoring clinical trial NCT05509816?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.